BioWorld A closer look BioWorld Asia BioWorld Science

BioWorld

Nektar’s rezpeg more than worth its SALT in alopecia phase IIb
With rezpegaldesleukin (rezpeg) phase IIb data in alopecia areata holding strong over time, backers of Nektar Therapeutics Inc. are hopeful that the biologic can do for the...

More in BioWorld

BioWorld Science

At AACR: Epigenetic fingerprints in metastases track tumor origin
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on machine...

More in BioWorld Science

A closer look

Med-tech financings steady at $8.8B in Q1, despite volume drop
Total med-tech financings reached $8.81 billion in the first quarter (Q1) 2026, a 6% decline from $9.33 billion in Q1 2025 but well above the post-downturn lows of recent...

More in A closer look

BioWorld Asia

Biogen amasses full felzartamab rights with $850M TJ deal
Biogen Inc. has consolidated full global rights to felzartamab through an $850 million deal with TJ Biopharma Co. Ltd. April 20, closing the chapter on a complex 10-year...

More in BioWorld Asia

BioWorld Insider podcast

The opioid crisis may not be front and center anymore, but it’s raging still. Elysium Therapeutics Inc. CEO Greg Sturmer talks about his firm’s candidate for a solution to the medical and societal problem.